Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mueller, M; Thorell, A; Claudel, T; Jha, P; Koefeler, H; Lackner, C; Hoesel, B; Fauler, G; Stojakovic, T; Einarsson, C; Marschall, HU; Trauner, M.
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
J Hepatol. 2015; 62(6):1398-1404
Doi: 10.1016/j.jhep.2014.12.034
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Müller Michaela
- Trauner Michael
- Co-Autor*innen der Med Uni Graz
- Claudel Thierry
- Fauler Günter
- Jha Pooja
- Köfeler Harald
- Lackner Karoline
- Stojakovic Tatjana
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Bile acids (BAs) are major regulators of hepatic BA and lipid metabolism but their mechanisms of action in non-alcoholic fatty liver disease (NAFLD) are still poorly understood. Here we aimed to explore the molecular and biochemical mechanisms of ursodeoxycholic acid (UDCA) in modulating the cross-talk between liver and visceral white adipose tissue (vWAT) regarding BA and cholesterol metabolism and fatty acid/lipid partitioning in morbidly obese NAFLD patients. In this randomized controlled pharmacodynamic study, we analyzed serum, liver and vWAT samples from 40 well-matched morbidly obese patients receiving UDCA (20 mg/kg/day) or no treatment three weeks prior to bariatric surgery. Short term UDCA administration stimulated BA synthesis by reducing circulating fibroblast growth factor 19 and farnesoid X receptor (FXR) activation, resulting in cholesterol 7α-hydroxylase induction mirrored by elevated C4 and 7α-hydroxycholesterol. Enhanced BA formation depleted hepatic and LDL-cholesterol with subsequent activation of the key enzyme of cholesterol synthesis 3-hydroxy-3-methylglutaryl-CoA reductase. Blunted FXR anti-lipogenic effects induced lipogenic stearoyl-CoA desaturase (SCD) in the liver, thereby increasing hepatic triglyceride content. In addition, induced SCD activity in vWAT shifted vWAT lipid metabolism towards generation of less toxic and more lipogenic monounsaturated fatty acids such as oleic acid. These data demonstrate that by exerting FXR-antagonistic effects, UDCA treatment in NAFLD patients strongly impacts on cholesterol and BA synthesis and induces neutral lipid accumulation in both liver and vWAT. Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Bile Acids and Salts - biosynthesis
- Bile Acids and Salts - metabolism
- Humans -
- Intra-Abdominal Fat - drug effects
- Intra-Abdominal Fat - metabolism
- Lipid Metabolism - drug effects
- Liver - drug effects
- Liver - metabolism
- Non-alcoholic Fatty Liver Disease - drug therapy
- Non-alcoholic Fatty Liver Disease - metabolism
- Obesity, Morbid - drug therapy
- Obesity, Morbid - metabolism
- Oleic Acid - metabolism
- Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors
- Stearoyl-CoA Desaturase - biosynthesis
- Ursodeoxycholic Acid - administration & dosage
- Ursodeoxycholic Acid - pharmacology
- Find related publications in this database (Keywords)
- Non-alcoholic fatty liver disease
- FGF19
- 3-hydroxy-3-methylglutaryl-CoA reductase
- Lipogenesis
- Stearoyl-CoA desaturase